Abstract Recent trials have shown the efficacy of trastuzumab deruxtecan (T-DXd) in HER2-negative patients. but there is not yet a way to identify which patients will best respond. especially with the inability of current HER2 IHC and FISH assays to accurately determine HER2 expression in the unamplified setting. Here. https://stnicksknives.shop/product-category/mini-presidio-ii-5750/